行業指南

人工智慧在藥物安全和藥物警戒的應用

Pharmacovigilance detects, evaluates and prevents suspected harm associated with medicines.

聆聽此指南AI 語音敘述 · ~2 min

本頁閱讀時間約2分鐘
  1. 概述
  2. 深入探討
  3. 現實世界的實施
  4. 人工智慧在藥物安全和藥物警戒領域的未來
  5. 付諸實踐
  6. 不斷探索
  7. 常見問題

概述

FDA FAERS and WHO VigiBase contain spontaneous reports; those reports and statistical signals do not establish incidence or causation.

深入探討

NLP can support extraction of suspected drug-event pairs from text, as demonstrated in a clinical narrative system evaluated in the 2018 n2c2 challenge. UMC describes VigiBase as a WHO database of reported events from health workers, the public and marketing authorisation holders. UMC signal management includes detection, validation, prioritisation, assessment and communication, combining computerized data mining with manual clinical assessment. ICH E2D(R1) minimum ICSR criteria are an event or observation, a suspect/interacting product, an identifiable patient and an identifiable reporter. A report or signal is not proof of causality.

現實世界的實施

A clinical NLP system can extract medication and adverse-event concepts and relations from narratives; one published n2c2 system was evaluated on that shared task.

MedDRA standardizes medical terms used in safety coding.

Disproportionality analysis screens report databases for drug-event reporting patterns that warrant assessment.

ICH E2D(R1) defines minimum criteria for an individual case safety report, while local rules determine reportability.

人工智慧在藥物安全和藥物警戒領域的未來

Use models as support for extracting, coding or prioritising information, with documented validation and expert assessment. This is a cautious workflow recommendation; the cited sources do not establish that fully automated safety decisions are appropriate.

付諸實踐

為什麼這很重要

  • 背景與規則. 產業背景決定了人工智慧創意能否與現實接觸。
  • 品質管控. 領域約束會影響可接受的錯誤率和監督模型。
  • 配裝選擇. 成功的部署使技術能力與第一線工作流程保持一致。

留意

  • 監理要求可能會使原本強大的原型失效。
  • 歷史資料可能會編碼損害特定社區的偏見。
  • 遺留系統可能會造成整合瓶頸和隱性成本。

後續步驟

  1. 讓領域專家參與從問題框架到評估的整個過程。
  2. 在啟動前設計審計追蹤和文件。
  3. 儘早驗證合規性和安全義務。
  4. 分階段推出,並有明確的停止和回滾標準。

不斷探索

免費電子報

獲取每日 AI 簡報

每個工作日上午提供三則經過驗證的 AI 新聞,以淺顯易懂的英文撰寫。永久免費,無廣告。

每個工作日一封電子郵件。一鍵取消訂閱。我們絕不出售或分享您的地址。

測試一下自己

Take the AI in Drug Safety and Pharmacovigilance quiz

每個答案皆有即時回饋,通過課程後可獲得具備可驗證 ID 的可分享證書。

開始測驗

支持免費的 AI 教育。AI Understanding 是一個 501(c)(3) 非營利組織——絕無廣告,絕無付費牆。 捐款

常見問題

What is AI in Drug Safety and Pharmacovigilance?

Pharmacovigilance detects, evaluates and prevents suspected harm associated with medicines. FDA FAERS and WHO VigiBase contain spontaneous reports; those reports and statistical signals do not establish incidence or causation.

藥物警戒的主要目標是什麼?

藥物警戒是一門監測藥物不良反應並採取行動防止患者受到傷害的科學,尤其是在藥物上市後。

In the published n2c2 clinical NLP system, what information did the system extract from narrative notes?

The paper describes a hybrid system for extracting medication and adverse-event concepts and relations from clinical narratives, evaluated in the 2018 n2c2 shared task.

不成比例分析在不良事件資料庫中偵測到什麼?

比例報告比等不成比例的衡量標準會標記藥物和經常意外出現的反應的組合,表明可能存在安全問題。

What is VigiBase, according to Uppsala Monitoring Centre?

UMC identifies VigiBase as the WHO global database of reported adverse events. A report is a suspicion and does not by itself confirm causality.

MedDRA 在藥物警戒管道中的用途是什麼?

MedDRA 是 NLP 系統將提取的反應映射到的標準化術語,因此可以對病例進行一致的比較和分析。